1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
EuBiologics Co., Ltd.

EuBiologics Co., Ltd.

KKRX:206650
7,330.00
KRW
-210.00
(-2.79%)
789.83EPS
10.94P/E
317.66BMarket Cap
Nov 06Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
297.43
188.79
281.76
467.34
971.27
1,209.36
1,016.7
1,111.24
1,514.3
1,904.2
2,632.36
4,074.81
3,333.19
Basic EPS, GAAP
-1,329.58
-333.13
-389.79
-190.5
147.51
-32.24
-2,146
-778
-30
-381
524
1,127
790.43
Free Cash Flow per Basic Share
-494.41
-777.98
-241.59
-375.46
-851.35
-541.07
-295.46
-472.91
-513.14
-472.31
860.54
877.89
165.36
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-757.12
-542.26
158.32
725.29
976.08
1,274.43
2,778.58
3,308.1
3,416.39
3,055.1
3,613.93
4,775.08
4,942.98
Tangible Book Value per Share
-801.62
-587.01
114.38
680.56
924.78
1,200.51
2,666.12
3,148.95
2,751.68
2,573.1
3,087.38
4,386.78
4,523.78
Basic Weighted Avg Shares
10
8
17
25
26
27
28
35
37
36
36
37
37
Sales/Revenue/Turnover
3,090
1,603
4,845
11,568
24,892
33,073
28,490
39,385
55,467
69,366
96,035
149,195
122,312
Operating Margin (%)
-58.91
-169.81
-142.71
-37.59
21.34
29.66
-20.93
-18.36
-6.79
11.1
35.74
40.66
35.39
Depreciation Expense
932
1,287
1,583
1,808
1,959
2,970
5,949
6,564
7,882
9,168
10,076
9,995
10,200
Net Income, GAAP
-13,813
-2,828
-6,702
-4,715
3,781
-882
-60,134
-27,574
-1,099
-13,879
19,117
41,264
29,005
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
23.31
32.48
Profit Margin (%)
-447.02
-176.46
-138.34
-40.76
15.19
-2.67
-211.07
-70.01
-1.98
-20.01
19.91
27.66
23.71
Working Capital
2,682
-5,697
1,672
9,588
3,893
-10,060
36,210
36,438
16,514
16,065
40,099
95,330
104,923
LT Debt
2,805
3,171
3,467
2,416
18,461
27,122
17,373
6,219
5,729
4,346
3,572
3,021
2,496
Total Equity
-16,226
-11,621
3,393
18,152
25,544
34,952
96,877
117,263
119,435
104,818
132,033
175,357
181,523
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
28
16.82
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
25.92
17.12
Return on Common Equity (%)
- -
- -
- -
-43.77
17.3
-2.91
-91.23
-25.43
-0.9
-11.77
15.71
26.85
17.19

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
974
765
1,160
LT Borrowings
- -
- -
- -
LT Finance Leases
3,021
- -
2,496
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
37
37
37
Market Capitalization
417,177
493,194
317,657

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
137,044
135,258
140,203
Cash, Cash Equivalents & STI
74,716
79,329
67,916
Accounts Receivable, Net
12,069
6,809
25,599
Inventories
38,304
40,028
34,204
Total Current Liabilities
41,715
33,889
35,280
Payables & Accruals
- -
- -
- -
ST Debt
974
765
1,160
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
63%
13.88%
32.81%
Free Cash Flow
-2.88%
-34.79%
2.38%
Net Income, GAAP
741.57%
178.2%
115.85%
Sales/Revenue/Turnover
67.32%
39.59%
55.35%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
15,189
7,867
36,152
36,827
96,035
2025
39,511
36,234
41,115
32,335
149,195
2026
15,643
33,220
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-99
-44
441
225.29
524
2025
430
211
475.79
11.29
1,127
2026
99.79
204
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Yeong-Ok Baik
Full Time Employees
397
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Bomnal-A-Chim B/D Seoul SL South Korea
IPO Date
Jan 24, 2017
Website
eubiologics.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
EuBiologics Co., Ltd. EuBiologics Co., Ltd. (206650.KQ) is a South Korea-based biopharmaceutical company that develops and supplies vaccines for global public health, with a focus on epidemic prevention in developing countries, and provides contract research, manufacturing, and testing services for biopharmaceuticals. Founded in 2010 and headquartered in Seoul, the company operates through two main segments: product development, offering oral cholera vaccines including the WHO-prequalified Euvichol, Euvichol Plus, and Euvichol-S; COVID-19 vaccines such as the approved EuCorVac-19 subunit vaccine; carrier protein vaccines like rCRM197 diphtheria toxoid; and pipelines including typhoid conjugate vaccine in Phase III, pneumococcal and meningococcal conjugate vaccines in early phases, and others targeting meningococcal infections and tetanus; alongside CRMO services encompassing cell line development, process and formulation development, GMP production of drug substances and products, analytical method validation, lot release and stability testing, and regulatory consulting for microbial- and mammalian cell-derived therapeutics including protein-based drugs and antibodies. It manufactures at advanced GMP-compliant facilities, including a second site inaugurated in 2019, and serves global markets with over 45 million doses of oral cholera vaccine supplied since 2015 prequalification. Recent developments include Korean regulatory approval in July 2025 for its UTPC multi-dose vaccine (export version), a new facility investment announcement in June 2025, a major supply contract in April 2025, leadership change with new representative director appointment in March 2025, and an investor presentation in May 2025.